Trillium Therapeutics Inc (TRIL)

[biocqr]

TRIL obtains exclusive rights develop preclinical compound to treat refractory epilepsy in the form of Dravet syndrome and related disorders...

NeuCyte Licenses Promising Novel Compound for Treatment of Refractory Epilepsy and Related Neurological Disorders

“This compound is an exceedingly promising antiseizure drug which, although in preclinical development, is quite efficacious in a wide variety of highly predictive seizure models,” said Roger J. Porter, MD, Adjunct Professor of Neurology at the University of Pennsylvania, former Deputy Director of NINDS, former Chairman of the White House Committee on Brain and Behavioral Sciences, and former President of American Epilepsy Society. “It may prove very effective for patients with epilepsy.” As a first-in-class compound with unique mechanism of action profiles, this drug candidate is likely to have activity across a variety of indications. The favorable efficacy and safety profile has also been validated by NeuCyte’s proprietary in vitro human iPSC-derived models.